Drug firm Bharat Parenterals on Saturday said it has received approval from the Drugs Controller General of India (DCGI) for favipiravir oral suspension, to be used for treatment of COVID-19 patients.
The company has received licence and authorisation from DCGI to manufacture and market favipiravir oral suspension l00mg/ml, Bharat Parenterals said in a regulatory filing.
Favipiravir, an antiviral drug, was approved in Japan in 2014 for the treatment of novel or re-emerging influenza virus infections.
Bombay High Court Orders Stay On Cutting 1,800 Trees In Nashik Tapovan Area For Simhastha Kumbh Mela
ACB Gets Go-Ahead To Proceed Against Mazgaon Court Additional Sessions Judge Aejazuddin Kazi As Corruption Probe Deepens
Television Actor Anuj Sachdeva Assaulted In Goregaon West, Alleges Police Inaction Despite FIR
Uttar Pradesh Cracks Down On Fertilizer Black Marketing, NSA Invoked Against Offenders
